These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 29943453

  • 21. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
    Marques-Piubelli ML, Tetzlaff MT, Nagarajan P, Duke TC, Glitza Oliva IC, Ledesma DA, Aung PP, Torres-Cabala CA, Wistuba II, Prieto VG, Nelson KC, Curry JL.
    J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S, Nguyen R, Opie JM, Andrews MC.
    Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
    Perret RE, Josselin N, Knol AC, Khammari A, Cassecuel J, Peuvrel L, Dreno B, Supported by GESTIM Nantes group of cutaneous adverse events induced by anticancer drugs.
    Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV.
    J Cutan Med Surg; 2021 May; 25(1):59-76. PubMed ID: 32746624
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A.
    Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
    [Abstract] [Full Text] [Related]

  • 34. Occult herpes simplex virus colonization of bullous dermatitides.
    Nikkels AF, Delvenne P, Herfs M, Pierard GE.
    Am J Clin Dermatol; 2008 Jun; 9(3):163-8. PubMed ID: 18429645
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V, Lamant L, Maisongrosse V, Delord JP.
    Ann Dermatol Venereol; 2013 Jun; 140(8-9):510-20. PubMed ID: 24034635
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Grover Disease Associated With Chemotherapy: Review of Potential Pathophysiology, Current Treatments, and Future Directions.
    Beer J, Rosenbach M.
    J Drugs Dermatol; 2020 Nov 01; 19(11):1056-1064. PubMed ID: 33196735
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.